Status:
UNKNOWN
Long Term Follow-up of Autologous Bone Marrow Mononuclear Cells Therapy in STEMI
Lead Sponsor:
Xijing Hospital
Conditions:
Myocardial Infarction
Eligibility:
All Genders
45-65 years
Phase:
PHASE1
PHASE2
Brief Summary
The benefit of current reperfusion therapies for ST-elevation myocardial infarction (STEMI) is limited by post-infarction left ventricular (LV) dysfunction. Many clinic trails showed the short term ou...
Detailed Description
The benefit of current reperfusion therapies for ST-elevation myocardial infarction (STEMI) is limited by post-infarction left ventricular (LV) dysfunction. Many clinic trails showed the short term ou...
Eligibility Criteria
Inclusion
- ST segment elevation myocardial infarction, according to the WHO definition.
- \<24 hour from the origin of symptoms.
- Single left anterior descending coronary artery disease.
- Successful revascularization of culprit lesion with PCI.
- Age between 45 and 65 years old.
- Written informed consent.
Exclusion
- Previous MI.
- Cardiomyopathy.
- Atrial fibrillation or fluctuation.
- Previous heart surgery.
- Severe valvular heart disease.
- Disease of the hematopoetic system.
- NYHA functional class IV at baseline.
- Severe renal, lung and liver disease or cancer.
- Significant coronary lesion in one or more major coronary vessels, requiring revascularization.
- Intra-cardiac thrombus.
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00626145
Start Date
March 1 2003
End Date
March 1 2008
Last Update
February 29 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Cardiology in Xijing Hospital
Xi'an, Shaanxi, China, 710032